文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

特发性肺纤维化与肺癌。系统评价和荟萃分析。

Idiopathic Pulmonary Fibrosis and Lung Cancer. A Systematic Review and Meta-analysis.

机构信息

1Department of Pulmonary, Critical Care and Sleep Medicine.

2Department of Hematology and Medical Oncology, Tisch Cancer Institute; and.

出版信息

Ann Am Thorac Soc. 2019 Aug;16(8):1041-1051. doi: 10.1513/AnnalsATS.201807-481OC.


DOI:10.1513/AnnalsATS.201807-481OC
PMID:30892054
Abstract

The association between idiopathic pulmonary fibrosis (IPF) and lung cancer has been previously reported. However, there is the potential for significant confounding by age and smoking, and an accurate summary risk estimate has not been previously ascertained. To determine the risk and burden of lung cancer in patients with IPF, accounting for known confounders. We conducted a comprehensive literature search of MEDLINE, EMBASE, and SCOPUS databases and used the Newcastle Ottawa criteria to assess study quality. We then assessed the quality of ascertainment of IPF cases based on modern consensus criteria. Data that relied on administrative claims or autopsies were excluded. We calculated summary risk estimates using a random effects model. Twenty-five cohort studies were included in the final analysis. The estimated adjusted incidence rate ratio from two studies was 6.42 (95% confidence interval [CI], 3.21-9.62) and accounted for age, sex, and smoking. The summary incidence rate from 11 studies was 2.07 per 100 person-years (95% CI, 1.46-2.67), and the summary mortality rate was 1.06 per 100 person-years (95% CI, 0.62-1.51) obtained from three studies. The summary prevalence from 11 studies was 13.74% (95% CI, 10.17-17.30), and the proportion of deaths attributable to lung cancer was 10.20 (95% CI, 8.52-11.87) and was obtained from nine studies. IPF is an increased independent risk factor for lung cancer, even after accounting for smoking. Further well-designed studies using modern consensus criteria are needed to explore mechanisms of this association.

摘要

特发性肺纤维化(IPF)与肺癌之间的关联先前已有报道。然而,年龄和吸烟因素可能会造成显著的混杂,因此此前并未确定准确的汇总风险估计值。为了确定 IPF 患者罹患肺癌的风险和负担,并考虑到已知的混杂因素,我们进行了全面的文献检索,检索了 MEDLINE、EMBASE 和 SCOPUS 数据库,并使用纽卡斯尔-渥太华量表评估了研究质量。然后,我们根据现代共识标准评估了 IPF 病例确定的质量。排除了依赖行政索赔或尸检的数据。我们使用随机效应模型计算了汇总风险估计值。最终分析共纳入了 25 项队列研究。两项研究的估计调整后发病率比值为 6.42(95%置信区间[CI],3.21-9.62),并考虑了年龄、性别和吸烟因素。11 项研究的汇总发病率为每 100 人年 2.07(95%CI,1.46-2.67),3 项研究的汇总死亡率为每 100 人年 1.06(95%CI,0.62-1.51)。11 项研究的汇总患病率为 13.74%(95%CI,10.17-17.30),9 项研究的肺癌归因死亡率比例为 10.20%(95%CI,8.52-11.87)。即使考虑到吸烟因素,IPF 仍是肺癌的独立危险因素。需要进一步采用现代共识标准设计良好的研究来探索这种关联的机制。

相似文献

[1]
Idiopathic Pulmonary Fibrosis and Lung Cancer. A Systematic Review and Meta-analysis.

Ann Am Thorac Soc. 2019-8

[2]
Idiopathic pulmonary fibrosis and diabetes mellitus: a meta-analysis and systematic review.

Respir Res. 2021-6-8

[3]
Characterizing Health Outcomes in Idiopathic Pulmonary Fibrosis using US Health Claims Data.

Respiration. 2020

[4]
Characterizing idiopathic pulmonary fibrosis patients using US Medicare-advantage health plan claims data.

BMC Pulm Med. 2019-1-10

[5]
Characteristics of lung cancer among patients with idiopathic pulmonary fibrosis and interstitial lung disease - analysis of institutional and population data.

Respir Res. 2018-10-3

[6]
Idiopathic Pulmonary Fibrosis in United States Automated Claims. Incidence, Prevalence, and Algorithm Validation.

Am J Respir Crit Care Med. 2015-11-15

[7]
Risk of cancer incidence in patients with idiopathic pulmonary fibrosis: A nationwide cohort study.

Respirology. 2021-2

[8]
Lung cancer in patients with idiopathic pulmonary fibrosis.

Pulm Pharmacol Ther. 2017-8

[9]
Lung cancer in idiopathic pulmonary fibrosis: A systematic review and meta-analysis.

PLoS One. 2018-8-16

[10]
Global incidence and prevalence of idiopathic pulmonary fibrosis.

Respir Res. 2021-7-7

引用本文的文献

[1]
Cancer-associated fibroblast marker signatures and stromal composition in usual interstitial pneumonia-associated lung adenocarcinoma: an analysis using a proteomic-immunohistochemical approach.

Virchows Arch. 2025-9-9

[2]
Concomitant Idiopathic Pulmonary Fibrosis and Lung Cancer: An Updated Narrative Review.

Adv Respir Med. 2025-8-18

[3]
Comorbidities' Effect on IPF: Pathogenesis and Management.

Biomedicines. 2025-6-1

[4]
A phase 1 study evaluating the safety, tolerability, and pharmacokinetics of the porcupine inhibitor, AZD5055.

iScience. 2025-6-6

[5]
Interstitial Lung Diseases and Lung Cancer: A Review on Similarities, Common Pathogenesis and Therapeutic Approach.

J Pers Med. 2025-5-21

[6]
The role of lung cancer in mortality rate in chronic fibrosing idiopathic interstitial pneumonia.

Sci Rep. 2025-5-14

[7]
Clinical analysis of patients with idiopathic pulmonary fibrosis concurrent with surgery resectable lung cancer: a retrospective cohort study from perspective of ILD physicians.

BMC Pulm Med. 2025-4-29

[8]
Decoding the complexity: mechanistic insights into comorbidities in idiopathic pulmonary fibrosis.

Eur Respir J. 2025-5-22

[9]
Cough and dyspnea management in pulmonary fibrosis.

Curr Opin Support Palliat Care. 2025-6-1

[10]
Risk factors and management of lung cancer in idiopathic pulmonary fibrosis: A comprehensive review.

Sarcoidosis Vasc Diffuse Lung Dis. 2025-3-18

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索